Novel agents for advanced pancreatic cancer

Akintunde Akinleye _, Chaitanya Iragavarapu, Muhammad Furqan, Shundong Cang and Delong Liu

PDF  |  HTML  |  How to cite

Oncotarget. 2015; 6:39521-39537. https://doi.org/10.18632/oncotarget.3999

Metrics: PDF 1924 views  |   HTML 4724 views  |   ?  


Akintunde Akinleye1, Chaitanya Iragavarapu1, Muhammad Furqan2, Shundong Cang3, Delong Liu4

1Division of Hematology/Oncology, Department of Medicine, New York Medical College, Valhalla, New York, United States

2Division of Hematology/Oncology, Department of Medicine, University of Iowa, Iowa City, Iowa, United States

3Department of Oncology, Henan Province People’s Hospital, Zhengzhou University, Zhengzhou, China

4Department of Oncology, Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China

Correspondence to:

Delong Liu, e-mail: [email protected]

Keywords: pancreatic cancer, IGF-1R

Received: February 27, 2015     Accepted: May 20, 2015     Published: June 03, 2015


Pancreatic cancer is relatively insensitive to conventional chemotherapy. Therefore, novel agents targeting dysregulated pathways (MAPK/ERK, EGFR, TGF-β, HEDGEHOG, NOTCH, IGF, PARP, PI3K/AKT, RAS, and Src) are being explored in clinical trials as monotherapy or in combination with cytotoxic chemotherapy. This review summarizes the most recent advances with the targeted therapies in the treatment of patients with advanced pancreatic cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3999